Evidence map›Paper›PMID 41634147›Full record

ReviewNature protocols2026

Secreted luciferases as a minimally invasive 3R-compliant tool for accurate monitoring of tumor burden.

Nastasja Merle, Imke Bullwinkel, Oleg Timofeev, Sabrina Elmshäuser, Thorsten Stiewe

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nastasja Merle *Institute of Molecular Oncology and Genomics Core Facility, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.ORCID http://orcid.org/0000-0003-4957-8463
Imke Bullwinkel *Institute of Molecular Oncology and Genomics Core Facility, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.ORCID http://orcid.org/0009-0005-2415-157X
Oleg TimofeevInstitute of Molecular Oncology and Genomics Core Facility, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Sabrina ElmshäuserInstitute of Molecular Oncology and Genomics Core Facility, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany.
Thorsten StieweInstitute of Molecular Oncology and Genomics Core Facility, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Philipps-University, Marburg, Germany. stiewe@uni-marburg.de.ORCID http://orcid.org/0000-0003-0134-7826

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) GRK 2573Deutsche Forschungsgemeinschaft (German Research Foundation) STI 182/15-1Von-Behring-Röntgen-Stiftung (Von Behring-Röntgen-Foundation) 71_0012
6 · The paper itself

Abstract

Preclinical mouse models are indispensable in cancer research, providing insights into tumor biology and therapeutic responses. This protocol describes a minimally invasive blood-based tumor monitoring approach using secreted luciferases for longitudinal tracking of tumor burden in transplantable xenografts and genetically engineered mouse models. Unlike intracellular luciferases used in bioluminescence imaging, secreted luciferases are actively released into circulation, enabling precise quantification from microliter-scale blood samples. We describe a transplantable model, where tumor cells are labeled in vitro using lentiviral transduction before engraftment. Orthogonal secreted luciferases enable multiplexed analysis of distinct tumor populations within a single host, reducing animal numbers and enhancing data density. We also describe an autochthonous lung cancer model, where intratracheal adenoviral delivery of Cre recombinase and CRISPR nucleases induces tumorigenesis through somatic genome editing while activating a conditional secreted luciferase reporter transgene. Tumor-bearing mice undergo routine blood sampling, with luciferase activity measured ex vivo to quantify viable tumor burden. Compared to imaging techniques, this method eliminates anesthesia and contrast agents, minimizing animal stress and enabling frequent monitoring with superior temporal resolution and reduced logistical complexity. The protocol requires only standard molecular biology skills and basic mouse handling expertise. While tumor labeling and growth duration is model dependent, blood sampling requires ~5 min per animal, with all samples from one cohort processed and measured together within 2 h. This approach provides an accessible, cost-effective and scalable alternative to imaging-based tumor monitoring, that is aligned with the 3Rs principles, offering a powerful and ethically sound platform for preclinical cancer research.

Indexed as

LuciferasesTumor BurdenAnimalsCell Line, TumorDisease Models, AnimalHumansLuminescent MeasurementsLung NeoplasmsMiceLuciferases

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.